-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...
Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a ...
DOUBLED over in pain, Amy Braid fought back tears as another wave of agonising cramps radiated through her body. But she wasn ...
Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025Expect to ...
The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...
Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million) ...
Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...
Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 million as of September 30, 2025 PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- ...
Learn more about whether Veracyte, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Learn more about whether BioMarin Pharmaceutical Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Investors seeking a stock unrelated to artificial intelligence should take a look at Boston Scientific.The historic rally in ...
For nearly a decade, despite regular visits to my GP practice where I detailed the pain I was experiencing, no one seemed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback